IL6 and neoplasm: Mechanistic studies reveal that pro-cancer immune pathways, including IL6-JAK-STAT3 and IFN-γ, are significantly suppressed in high-risk patients (NES < -1.5, P < 0.01), while the infiltration levels of 19 key immune cells, such as CD8 + T cells and dendritic cells, are diminished in the tumor microenvironment, creating a vicious cycle of immune evasion and immune suppression.